Cargando…
2178 Drug development core facilitates institutional collaboration and translational science innovation
OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799261/ http://dx.doi.org/10.1017/cts.2018.68 |
_version_ | 1783460246363045888 |
---|---|
author | Morse, Gene Puzanov, Igor Gudkov, Andrei DiFrancesco, Robin Jusko, William Ernstoff, Marc Mohler, James Murphy, Timothy Bies, Robert |
author_facet | Morse, Gene Puzanov, Igor Gudkov, Andrei DiFrancesco, Robin Jusko, William Ernstoff, Marc Mohler, James Murphy, Timothy Bies, Robert |
author_sort | Morse, Gene |
collection | PubMed |
description | OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science Institute (CTSI) has implemented a Drug Development Core (DDC) with goals that foster team science and collaboration, optimize laboratory use, and networks investigators. Our goals are to foster collaborations within the region and with other CTSAs. METHODS/STUDY POPULATION: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. RESULTS/ANTICIPATED RESULTS: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. DISCUSSION/SIGNIFICANCE OF IMPACT: The CTSI DDC was well received by investigators. The request process fosters collaboration among researchers with similar interests and identifies core laboratory resources that add innovation to ongoing research, funding applications, education, and interinstitutional planning. |
format | Online Article Text |
id | pubmed-6799261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-67992612019-10-28 2178 Drug development core facilitates institutional collaboration and translational science innovation Morse, Gene Puzanov, Igor Gudkov, Andrei DiFrancesco, Robin Jusko, William Ernstoff, Marc Mohler, James Murphy, Timothy Bies, Robert J Clin Transl Sci Basic/Translational Science/Team Science OBJECTIVES/SPECIFIC AIMS: Drug development is a common research pursuit for basic and clinical scientists that interfaces diagnostic/therapeutic challenges with funding agencies, pharmaceutical industry, regulatory systems, and education. The University at Buffalo Clinical and Translational Science Institute (CTSI) has implemented a Drug Development Core (DDC) with goals that foster team science and collaboration, optimize laboratory use, and networks investigators. Our goals are to foster collaborations within the region and with other CTSAs. METHODS/STUDY POPULATION: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. RESULTS/ANTICIPATED RESULTS: The DDC met with 300 potential investigators from 14 departments and several local companies. There were 35 portal requests from 15 departments and 7 companies; 8 were from training programs. For 28 requests, a reviewer provided consultation, while 7 required discussions and review of data. DDC assisted with 15 grant applications (outcomes pending), 10 industry-related new drug development requests and 1 regulatory review. Curriculum reviews noted overlap and gaps. Cross-institute opportunities for M.D.-Ph.D. research mentoring were identified. DISCUSSION/SIGNIFICANCE OF IMPACT: The CTSI DDC was well received by investigators. The request process fosters collaboration among researchers with similar interests and identifies core laboratory resources that add innovation to ongoing research, funding applications, education, and interinstitutional planning. Cambridge University Press 2018-11-21 /pmc/articles/PMC6799261/ http://dx.doi.org/10.1017/cts.2018.68 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Basic/Translational Science/Team Science Morse, Gene Puzanov, Igor Gudkov, Andrei DiFrancesco, Robin Jusko, William Ernstoff, Marc Mohler, James Murphy, Timothy Bies, Robert 2178 Drug development core facilitates institutional collaboration and translational science innovation |
title | 2178 Drug development core facilitates institutional collaboration and translational science innovation |
title_full | 2178 Drug development core facilitates institutional collaboration and translational science innovation |
title_fullStr | 2178 Drug development core facilitates institutional collaboration and translational science innovation |
title_full_unstemmed | 2178 Drug development core facilitates institutional collaboration and translational science innovation |
title_short | 2178 Drug development core facilitates institutional collaboration and translational science innovation |
title_sort | 2178 drug development core facilitates institutional collaboration and translational science innovation |
topic | Basic/Translational Science/Team Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799261/ http://dx.doi.org/10.1017/cts.2018.68 |
work_keys_str_mv | AT morsegene 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT puzanovigor 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT gudkovandrei 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT difrancescorobin 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT juskowilliam 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT ernstoffmarc 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT mohlerjames 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT murphytimothy 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation AT biesrobert 2178drugdevelopmentcorefacilitatesinstitutionalcollaborationandtranslationalscienceinnovation |